Absci Corp. (ABSI)
NASDAQ:ABSI
Top Page
AbSci
(NASDAQ:ABSI)
Select Model
Select Model
Rating:56Neutral
Price Target:
$3.00
▼(-1.64% Downside)
Action:ReiteratedDate:03/26/26
The score is held down primarily by weak financial performance (ongoing losses, high cash burn, and unstable revenue), partially offset by a positive, catalyst-rich earnings update with stated runway into 2028 and improving near-term technical momentum. Valuation provides limited support due to negative earnings and no dividend yield data.
Positive Factors
Platform differentiation
OriginOne's de novo, lab-in-loop antibody design capability is a durable competitive asset: it materially shortens discovery cycles, reduces lead generation costs, and can create proprietary targets and outputs that attract partners. Over months, reproducible platform output can sustain deal flow and lower marginal program costs.
Negative Factors
High cash burn
Consistently large negative operating and free cash flow is a durable headwind: it forces recurring external financing, partnership dependence, or asset sales, which can dilute shareholders or constrain strategic choices. Continued burn magnifies risk if clinical timelines slip or costs rise, pressuring runway beyond projections.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform differentiation
OriginOne's de novo, lab-in-loop antibody design capability is a durable competitive asset: it materially shortens discovery cycles, reduces lead generation costs, and can create proprietary targets and outputs that attract partners. Over months, reproducible platform output can sustain deal flow and lower marginal program costs.
Read all positive factors
AbSci (ABSI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$456.00M
Dividend YieldN/A
Average Volume (3M)4.03M
Price to Earnings (P/E)―
Beta (1Y)2.13
Revenue Growth-33.09%
EPS Growth3.38%
CountryUS
Employees156
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.20
Shares Outstanding153,021,260
10 Day Avg. Volume3,405,149
30 Day Avg. Volume4,033,709
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)2.52
Price to Sales (P/S)170.48
P/FCF Ratio-5.08
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue166.89
Enterprise Value/Gross Profit-12.68
Enterprise Value/Ebitda-4.14
Forecast
1Y Price Target
$7.64Price Target Upside150.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.78
Revenue Forecast (FY)$9.67M
AbSci Business Overview & Revenue Model
Company Description
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creati...
How the Company Makes Money
AbSci makes money primarily by providing drug discovery and development-enabling services to biopharmaceutical partners using its AI-guided biologics design platform and associated wet-lab capabilities. Revenue is generally generated through partn...
AbSci Earnings Call Summary
Earnings Call Date:Mar 24, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 19, 2026
Earnings Call Sentiment Positive
The call conveyed substantial progress and multiple near-term catalysts: first-in-human dosing for ABS-201 with favorable emerging safety/PK, an expanded indication into endometriosis with a planned Phase 2, published platform validation for de novo antibody design, strong survey-based commercial interest, and a stated cash runway into 2028. Counterbalancing these positives are modest current revenue, increased R&D spend (+37.5% YoY for the quarter), a sequential cash decline (-5.4%), early-stage clinical evidence with limited exposure, and competitive/regulatory uncertainties. On balance, the momentum on clinical advancement, platform differentiation, and market interest outweigh the present financial burn and early-stage risks.Positive Updates
Clinical Progress — ABS-201 Dosing and Early Safety/PK
Dosed first three SAD cohorts (roughly ~24 participants estimated) in ongoing Phase 1/2a headline trial; ABS-201 reported as well tolerated with favorable emerging safety data and emerging PK that supports the modeled dosing regimen. Planned milestones: preliminary safety/tolerability/PK data in H1 2026, interim 13-week proof-of-concept (POC) in H2 2026, and full 26-week POC in early 2027. Trial design enrolls up to 227 participants and includes SAD and MAD portions with MAD powered for AGA POC.
Negative Updates
Limited Near-Term Revenue
Q4 revenue was modest at $700,000, reflecting early-stage commercialization and reliance on partnered program revenue rather than product sales.
Read all updates
Q4-2025 Updates
Positive
Negative
Clinical Progress — ABS-201 Dosing and Early Safety/PK
Dosed first three SAD cohorts (roughly ~24 participants estimated) in ongoing Phase 1/2a headline trial; ABS-201 reported as well tolerated with favorable emerging safety data and emerging PK that supports the modeled dosing regimen. Planned milestones: preliminary safety/tolerability/PK data in H1 2026, interim 13-week proof-of-concept (POC) in H2 2026, and full 26-week POC in early 2027. Trial design enrolls up to 227 participants and includes SAD and MAD portions with MAD powered for AGA POC.
Read all positive updates
Company Guidance
Management provided specific clinical and commercial guidance for ABS‑201: the randomized, double‑blind Phase 1/2a (up to 227 healthy volunteers with/without AGA) has dosed the first three SAD cohorts (roughly ~24 participants), is evaluating four IV SAD dose groups followed by three SC MAD groups, and is on track to dose SAD cohort 4 and the first MAD cohort; preliminary safety/tolerability/PK data are expected in H1 2026, an interim 13‑week proof‑of‑concept readout in H2 2026, full 26‑week POC data in early 2027, and safety/PK from this study is planned to support initiation of a Phase 2 endometriosis trial in Q4 2026 (interim endo readout in 2027); key product metrics include a 3–4× longer preclinical half‑life vs a competitor, an anticipated dosing regimen of ~2–3 subcutaneous administrations over ~6 months with 2–3 year durability, a target efficacy comparable to high‑dose oral minoxidil (~35–40 hairs/cm²), and platform efficiencies of ~2 years and ~$15M to IND versus typical 4–6 years and ≥$50M; commercial and market figures cited include a U.S. AGA addressable population of ~15–18M (annual treatable volume 5–9M), consumer survey of 610 participants showing 87% of men/69% of women extremely/very likely to ask about ABS‑201 (rising to 92%/89% among oral minoxidil users), >30,000 potential U.S. retail locations, a U.S. TAM conceptually exceeding $25B, and endometriosis prevalence ~10% of women of reproductive age worldwide; financials: Q4 revenue $0.7M, R&D $25.3M (vs $18.4M prior year), SG&A $8.6M (vs $8.8M), $5.1M gain on contingent consideration (net $8.7M unrestricted), cash/cash equivalents/marketable securities $144.3M (Sept 30, 2025: $152.5M), and management believes runway into 2028.AbSci Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.80M | 4.53M | 5.72M | 5.75M | 4.78M |
| Gross Profit | -8.94M | -57.92M | -41.85M | -53.16M | -39.80M |
| EBITDA | -112.98M | -94.10M | -79.68M | -93.71M | -67.68M |
| Net Income | -115.18M | -103.11M | -110.57M | -104.90M | -100.96M |
Balance Sheet | |||||
| Total Assets | 216.30M | 213.61M | 217.30M | 321.01M | 426.19M |
| Cash, Cash Equivalents and Short-Term Investments | 144.29M | 112.42M | 97.66M | 164.43M | 252.57M |
| Total Debt | 5.30M | 10.11M | 15.88M | 22.98M | 20.01M |
| Total Liabilities | 26.85M | 34.48M | 41.12M | 46.59M | 60.09M |
| Stockholders Equity | 189.45M | 179.13M | 176.18M | 274.41M | 366.11M |
Cash Flow | |||||
| Free Cash Flow | -94.03M | -72.81M | -65.50M | -97.51M | -98.64M |
| Operating Cash Flow | -92.92M | -72.40M | -64.64M | -81.34M | -60.60M |
| Investing Cash Flow | -50.16M | -41.58M | 81.94M | -126.98M | -67.38M |
| Financing Cash Flow | 105.95M | 82.53M | -4.48M | 5.24M | 336.19M |
AbSci Technical Analysis
Positive
3.05
Price Trends
2.77
Positive
3.04
Positive
3.09
Negative
Market Momentum
0.07
Negative
56.29
Neutral
46.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABSI, the sentiment is Positive. The current price of 3.05 is above the 20-day moving average (MA) of 2.94, above the 50-day MA of 2.77, and below the 200-day MA of 3.09, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 56.29 is Neutral, neither overbought nor oversold. The STOCH value of 46.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ABSI.
AbSci Risk Analysis
AbSci disclosed 83 risk factors in its most recent earnings report. AbSci reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AbSci Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $456.00M | -4.14 | -59.68% | ― | -33.09% | 3.38% | |
52 Neutral | $500.82M | -3.10 | -47.27% | ― | ― | ― | |
52 Neutral | $749.93M | -7.71 | -32.72% | ― | ― | -40.26% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $396.55M | -1.84 | -99.00% | ― | 407.86% | 30.35% | |
47 Neutral | $475.15M | -3.14 | 76.03% | ― | 6.35% | 39.57% |
* Healthcare Sector Average
ABSI
AbSci
3.05
-0.07
-2.24%
AUTL
Autolus Therapeutics
1.47
0.07
5.00%
ADCT
ADC Therapeutics
3.81
2.60
214.88%
FDMT
4D Molecular Therapeutics
10.04
6.94
223.87%
DSGN
Design Therapeutics
12.35
9.03
271.99%
AbSci Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Absci Reports 2025 Results and Advances ABS-201 Program
Positive
Mar 24, 2026
On March 24, 2026, Absci reported fourth quarter and full-year 2025 results, highlighting clinical progress on ABS-201, its anti-PRLR antibody for androgenetic alopecia and endometriosis, including successful dosing of the first three cohorts in t...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
Absci Updates Leadership Indemnification Agreements Amid Governance Focus
Positive
Mar 6, 2026
On March 6, 2026, Absci’s board approved amended and restated indemnification agreements for its directors and officers under Delaware law, refining change-of-control definitions, extending coverage for separate counsel in such events, and a...
Business Operations and Strategy
Absci Showcases Generative AI Drug Platform and Pipeline
Positive
Jan 14, 2026
On January 14, 2026, Absci Corporation presented a business update at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its generative AI-driven drug creation platform and the progress of its clinical pipeline. Management emphasized ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.